Phase II open label study assessing Piclidenoson
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Piclidenoson (Primary)
- Indications Oculocerebrorenal syndrome
- Focus Therapeutic Use
- 14 Apr 2025 According to Can-Fite Biopharma media release, A Phase II design has been completed and preparatory work is being undertaken to initiate the study that will be conducted by Dr. Franchesca Emma from the Division of Nephrology, Bambino Gesu Children's Hospital-IRCCS Rome Italy.
- 26 Mar 2025 New trial record
- 19 Mar 2025 According to Can-Fite Biopharma media release, Dr. Franchesca Emma from the Division of Nephrology, Bambino Gesu Childrens Hospital - IRCCS Rome Italy, will be the principal investigator of the study.